KYMR insider sale notice: 80,000 shares via option exercise

KYR Medicines, Inc. (KYMR) reported a Section 144 notice indicating an intended sale of 80,000 shares of Common Stock on 07/01/2026 arising from an exercise of stock options with cash as the payment method.

Rhea-AI Filing Summary

KYR Medicines, Inc. (KYMR) reported a Section 144 notice indicating an intended sale of 80,000 shares of Common Stock on 07/01/2026 arising from an exercise of stock options with cash as the payment method. The filing also records a prior sale of 30,000 shares on 04/29/2026.

The filing lists an aggregate dollar figure of $9,143,200.00 and a share count of 82,257,588 tied to 07/01/2026. The notice names Nello Mainolfi in the recent sale record.

Insights

Insider Transactions Specialist

Form 144 discloses an option-related sale plan and a recent insider sale.

The filing shows an intended disposition of 80,000 shares on 07/01/2026 described as resulting from an exercise of stock options with cash noted as the payment type. It also records a prior sale of 30,000 shares on 04/29/2026.

Cash‑flow treatment and whether the 80,000 shares will be sold in the open market or via other methods is not detailed in the excerpt; subsequent regulatory filings or broker confirmations may disclose execution method and timing.

Key Figures

Planned sale: 80,000 shares Aggregate figure listed: $9,143,200.00 Shares outstanding (row): 82,257,588 +2 more

5 metrics

Planned sale 80,000 shares intended sale on <date>07/01/2026</date> from an exercise of stock options

Aggregate figure listed $9,143,200.00 appears in the row tied to the 80,000 shares and <date>07/01/2026</date>

Shares outstanding (row) 82,257,588 listed alongside the 80,000 share entry with <date>07/01/2026</date>

Recent sale 30,000 shares sold on <date>04/29/2026</date> by Nello Mainolfi

Proceeds associated with recent sale $2,435,370.00 appears in the "Securities Sold During The Past 3 Months" row for 30,000 shares

Key Terms

Form 144, exercise of stock options, Issuer

3 terms

Form 144 regulatory

"Section header and filing type statement"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

exercise of stock options financial

"Securities To Be Sold row showing the reason for sale"

Issuer regulatory

"Transaction party column in Securities To Be Sold row"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does KYMR's Form 144 report about the planned sale?

The Form 144 reports an intended sale of 80,000 shares on 07/01/2026 tied to an exercise of stock options. The filing lists $9,143,200.00 alongside a share count of 82,257,588 in the same row.

Who appears in the filing's recent sale history for KYMR?

The filing lists Nello Mainolfi as having sold 30,000 shares on 04/29/2026 with an associated dollar figure of $2,435,370.00. This appears in the "Securities Sold During The Past 3 Months" section.

Are the 80,000 shares being sold by KYMR newly issued or from an exercise?

The excerpt states the 80,000 shares are associated with an exercise of stock options and lists Issuer in the transaction line. The payment method is shown as Cash in the provided row.

Does the Form 144 specify how the 80,000 shares will be sold?

The excerpt indicates method as Cash for the option exercise but does not detail the distribution method (open‑market, block trade, or broker sale). Execution mechanics and timing are not included in the provided text.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 08:33 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001821189
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Kymera Therapeutics, Inc.
SEC File Number	001-39460
Address of Issuer	500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MASSACHUSETTS 02472
Phone	857-285-5314
Name of Person for Whose Account the Securities are To Be Sold	Mainolfi Nello
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	80000	9143200.00	82257588	07/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/01/2026	Exercise of stock options	Issuer			80000	07/01/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Nello Mainolfi 500 NORTH BEACON STREET 4TH FLOOR WATERTOWN MA 02472	Common	04/29/2026	30000	2435370.00

144: Remarks and Signature

Remarks
Date of Notice	07/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/24/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for Nello Mainolfi
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)